A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
← catalyst calendarNCT06649045 · readout ≤ 103 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
600estimated
Sites
66
Countries
Argentina, Brazil, China +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-22 | actual | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- OSA
- Overweight or Obesity
Interventions
- Drug: Orforglipron — also filed as LY3502970
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in Apnea-Hypopnea Index (AHI)
measured Baseline to Week 52
Publications
- PMID 42383207 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed